|Articles|November 14, 2018
CSF-1 drops demonstrate efficacy, safety in clinical studies for treatment of presbyopia
Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at OIS@AAO 2018 in Chicago.
Advertisement
Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at OIS@AAO 2018 in Chicago.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Phase 3 NORTHSTAR Trial Launches for Gildeuretinol in Stargardt Disease
2
Rising Star: Introducing Viha Vig, MBChB
3
Self-Screening for Ocular Surface Malignancies Using a Smartphone
4
Everest Medicines acquires Greater China rights to Aceclidine Presbyopia Eye Drop (VIZZ)
5

















